NMES

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, May 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, May 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

Zynex Receives FDA Clearance for its Next Generation NMES Device

Retrieved on: 
Tuesday, February 6, 2024
Rehabilitation, NMES, History, Exercise, Patient, FDA, Food, Pain management, Sale, Medical imaging

(NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.

Key Points: 
  • (NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.
  • NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
  • The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
  • "The M-Wave introduces the next evolution in NMES devices, allowing for more customizable treatments within clinical and home settings," said Thomas Sandgaard, CEO at Zynex Medical.

MANAMED Receives Expanded 510(k) Clearance for ManaFlexx 2

Retrieved on: 
Thursday, November 16, 2023
Transcutaneous electrical nerve stimulation, Arm, Chronic pain, TENS, EMS, US Foods, Exercise, Shoulder, FDA, Arthritis, System, Neurostimulation, Pain, NMES, Athlete, Leg, Skin, Poultry farming

DENTON, Texas, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) has granted over-the-counter marketing clearance for the ManaFlexx 2®, an Electrical Stimulation (EMS) device, from MANAMED®, LLC. ManaFlexx 2 is a compact medical device that delivers electrical pulses to the user's skin through the company's patented wireless technology for two distinct uses. The expanded indication applies to both ManaFlexx 2 device's indications: Neuromuscular Electrical Stimulation (NMES) and Transcutaneous Electrical Nerve Stimulation (TENS).

Key Points: 
  • DENTON, Texas, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) has granted over-the-counter marketing clearance for the ManaFlexx 2®, an Electrical Stimulation (EMS) device, from MANAMED®, LLC.
  • ManaFlexx 2 is a compact medical device that delivers electrical pulses to the user's skin through the company's patented wireless technology for two distinct uses.
  • The expanded indication applies to both ManaFlexx 2 device's indications: Neuromuscular Electrical Stimulation (NMES) and Transcutaneous Electrical Nerve Stimulation (TENS).
  • This expanded indication joins the previous FDA clearance granted for the noninvasive device as an adjunctive treatment in the management of post-surgical and post- traumatic acute pain.

Zynex Submits FDA Application for its Next Generation NMES Device

Retrieved on: 
Monday, November 13, 2023
Sale, NMES, M-Wave, Pain management, Rehabilitation, Patient, Food, FDA, Medical device, Medical imaging

The M-Wave is set to replace its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.

Key Points: 
  • The M-Wave is set to replace its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
  • I believe that this next-generation device will be able to build upon the need for customizable NMES treatments in clinical and home settings."
  • The 510(k) application submission represents a significant milestone in Zynex Medical's commitment to delivering cutting-edge medical devices.
  • This application demonstrates the company's dedication to ensuring that patients have access to the latest innovations in medical technology.

Signifier Medical Technologies Announces Upcoming Publication of Randomized Controlled Trial Results Examining High-Intensity (Active) Vs. Low-Intensity (Sham) Neuromuscular Electrical Stimulation in Patients for 6 Weeks

Retrieved on: 
Thursday, November 2, 2023
Neurology, Venture Capital, Health, Medical Devices, Health Technology, Professional Services, Clinical Trials, Other Health, Supine position, NMES, Research, Clinical trial, Body mass index, Signified and signifier, PAP, Sleep, Somnolence, Health technology, Patient, Randomized controlled trial, Obstructive sleep apnea, AEGIS, Pharmaceutical industry, Birth control

The objective of the trial was to determine whether patients with mild obstructive sleep apnea (OSA) would adhere to eXciteOSA, a daytime neuromuscular electrical stimulation (NMES) therapy.

Key Points: 
  • The objective of the trial was to determine whether patients with mild obstructive sleep apnea (OSA) would adhere to eXciteOSA, a daytime neuromuscular electrical stimulation (NMES) therapy.
  • This trial demonstrates the potential of Signifier Medical’s innovative medical technology to significantly improve the lives of individuals suffering from obstructive sleep apnea (OSA).
  • The trial involved 40 patients and was conducted in collaboration with a network of renowned medical institutions and healthcare professionals.
  • Signifier Medical Technologies remains dedicated to further research, development, and collaboration with healthcare professionals to continue advancing medical technology and improving patient outcomes.

Neuromuscular Electrical Stimulation as a Treatment for Obstructive Sleep Apnea Gains Traction With a Recently Announced World Sleep 2023 Congress Symposium

Retrieved on: 
Tuesday, September 26, 2023
Health, General Health, Sleep, Obstructive sleep apnea, Health technology, Clinical trial, Quality of life, Research, World Sleep Day, NMES, Congress, Patient, Treatment, Electricity, Pharmaceutical industry

Since its FDA De Novo authorization in 2021, Signifier Medical has been a leader in applying neuromuscular electrical stimulation (NMES) to obstructive sleep apnea (OSA).

Key Points: 
  • Since its FDA De Novo authorization in 2021, Signifier Medical has been a leader in applying neuromuscular electrical stimulation (NMES) to obstructive sleep apnea (OSA).
  • The NMES-for-OSA World Sleep presentation will be led by doctors Alexandre Abreu, Atul Malhotra, Adrian Williams, Marina Carrasco-Llatas, and Naresh Punjabi.
  • "We look forward to sharing our research and engaging with sleep medicine professionals from around the world at the World Sleep 2023 Congress," added Dr. Naresh Punjabi.
  • The World Sleep 2023 Congress is scheduled for October 20-25, 2023, in Rio de Janeiro, Brazil.

Comprehensive Report on Electrical Muscle Stimulation Market 2024-2034 Reveals Emerging Trends and Key Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Medical Devices, TENS, FES, Rehabilitation, NMES, SWOT, SWOT analysis, Pain management, Growth & Opportunity Project, R, D, Medical device, Retail

The "The Global Electrical Muscle Stimulation Market 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Electrical Muscle Stimulation Market 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • The recently released report titled "The Global Electrical Muscle Stimulation Market 2024-2034" presents a comprehensive analysis of the global muscle stimulator devices market.
  • It offers a deep dive into market size, growth trends, emerging technologies, regulatory landscape, competitive dynamics, and leading companies.
  • The report delves into various types of muscle stimulators, including transcutaneous electrical nerve stimulation (TENS) devices, neuromuscular electrical stimulators (NMES), functional electrical stimulation (FES), interferential current (IFC) devices, microcurrent stimulators, and more.

Centura Study Finds NeuFit Direct Current Neuromuscular Electrical Stimulation to improve spasticity and functional outcomes in individuals with multiple sclerosis (MS)

Retrieved on: 
Thursday, August 24, 2023
Exercise, Anecdote, UTI, Spinal cord, Diabetic neuropathy, DSM-IV codes, Quality of life, Weakness, PT, Disability studies, Brain, Research, Facial muscles, Falls, NMES, Doctor of Philosophy, PNS, MS, EDSS, Clonus, Motion, Patient, Mechanoreceptor, Clutch (eggs), FDA, DPT, Spasticity, Atrophy, Peripheral nervous system, Dietary supplement, Medical device, Nursing

AUSTIN, Texas, Aug. 24, 2023 /PRNewswire/ -- A case series conducted by Dr. Courtney Ellerbusch, PT, DPT, of Centura Home Health (Colorado) on MS patients finds quantitative improvements in strength, spasticity, and range of motion over a series of 18 treatments with Neubie Direct Current neuromuscular electrical stimulation (NMES) therapy.

Key Points: 
  • These issues can contribute to muscle imbalances, postural problems and asymmetries, difficulty with activities of daily living, and falls.
  • "I [completed] this project for the individuals who face a daily reality in MS that has changed everything about their lives.
  • The Neubie Device uses direct current electrical stimulation to communicate with mechanoreceptors of the peripheral nervous system (PNS).
  • This action supports functional changes for a variety of FDA-cleared indications, including neuromuscular re-education and increasing range of motion.